argenx (ARGX) vs Gilead Sciences (GILD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Gilead Sciences (GILD) has outperformed argenx (ARGX) over the past year, gaining 24.4% versus a gain of 2.5%. Over five years, ARGX leads with a +178.7% price change compared with +117.5% for GILD. Gilead Sciences is the larger company by market cap ($182.40 billion vs $51.48 billion), about 3.5 times the size.
On valuation, Gilead Sciences trades at a lower forward P/E (14.9x vs 23.6x for argenx). Gilead Sciences pays a dividend yielding 2.19%, while argenx does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARGX | GILD |
|---|---|---|
| Share price | $818.63 | $147.10 |
| Market cap | $51.48B | $182.40B |
| 1-day change | -11.83% | +0.17% |
| YTD return | -2.65% | +19.85% |
| 1-year return | +2.46% | +24.40% |
| 5-year return | +178.69% | +117.51% |
| P/E ratio (TTM) | 31.20 | — |
| Forward P/E | 23.58 | 14.87 |
| EPS (TTM) | $26.24 | $-2.65 |
| Dividend yield | 0.00% | 2.19% |
| Annual dividend | $0.00 | $3.22 |
| Revenue (latest FY) | — | $29.44B |
| Revenue growth (YoY) | — | +2.40% |
| Net income (latest FY) | $1.29B | $8.51B |
| Gross margin | — | 78.83% |
| Operating margin | — | 34.04% |
| Net margin | — | 28.90% |
| 52-week high | $1,072.75 | $157.29 |
| 52-week low | $661.85 | $114.02 |
| Distance from 52-week high | -23.69% | -6.48% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +43.17% | +8.27% |
| Average volume | 283.40K | 5.99M |
| Shares outstanding | 62.89M | 1.24B |
| Employees | 1,863 | 17,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Gilead Sciences is about 3.5 times larger than argenx by market value ($182.40B vs $51.48B).
- GILD has outperformed ARGX by 21.9 percentage points over the past year.
- Gilead Sciences offers a meaningfully higher dividend yield (2.19% vs 0.00%).
About argenx
ARGX stock →argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,863 employees
About Gilead Sciences
GILD stock →Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 17,000 employees
ARGX vs GILD FAQ
Which is bigger, argenx or Gilead Sciences?
Gilead Sciences (GILD) is larger, with a market capitalization of $182.40B compared with $51.48B for argenx (ARGX).
Which stock has performed better over the past year, ARGX or GILD?
GILD returned +24.40% over the past 12 months, compared with +2.46% for ARGX (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, argenx or Gilead Sciences?
Gilead Sciences pays a dividend yielding 2.19%, while argenx does not currently pay a regular dividend.
Are argenx and Gilead Sciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.